指南与共识膀胱癌与上尿路尿路上皮癌

非转移性肌层浸润性膀胱癌的治疗:AUA/ASCO/ASTRO/SUO 指南

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.
指南 / 共识 · J Urol · 2017-04-26

该多学科循证指南针对临床非转移性肌层浸润性膀胱癌,聚焦以治愈为目的的评估、治疗与监测。指南基于系统评价及证据等级 A、B、C 制定推荐,并首次以风险分层临床框架管理肌层浸润性尿路上皮癌。

要点

  • 指南由 AUA、ASCO、ASTRO、SUO 联合制定,基于系统评价与证据等级。
  • 推荐强度分为强推荐、中等推荐与条件性推荐,另有临床原则与专家意见。
  • 这是首个基于风险分层临床框架的肌层浸润性膀胱癌循证指南。

核心结论

  • 肌层浸润性膀胱癌的诊疗强度与范围应聚焦于患者、疾病及治疗反应特征。
  • 该指南旨在提升临床医生评估与治疗每位患者的能力,但未来试验中更高质量的证据对改善此类患者的照护水平至关重要。

研究设计与样本

  • 该指南为多学科循证指南,针对临床非转移性肌层浸润性膀胱癌。
  • 采用系统评价制定,利用了医疗保健研究与质量局的科研证据,并由作者及顾问方法学家补充。

主要发现

  • 美国泌尿外科学会、美国临床肿瘤学会、美国放射肿瘤学会与泌尿肿瘤学会首次针对任一类型恶性肿瘤制定了基于风险分层临床框架的循证指南。
  • 文件设计为与相关治疗算法联合使用。

关键数值与推荐

  • 证据声明基于证据等级 A、B 或 C,并分别指定为强推荐、中等推荐与条件性推荐。
  • 其他声明以临床原则或专家意见形式呈现。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This multidisciplinary, evidence-based guideline for clinically non-metastatic muscle-invasive bladder cancer focuses on the evaluation, treatment and surveillance of muscle-invasive bladder cancer guided toward curative intent. MATERIALS AND METHODS: A systematic review utilizing research from the Agency for Healthcare Research and Quality as well as additional supplementation by the authors and consultant methodologists was used to develop the guideline. Evidence-based statements were based on body of evidence strengths Grade A, B or C and were designated as Strong, Moderate and Conditional Recommendations with additional statements presented in the form of Clinical Principles or Expert Opinions. RESULTS: For the first time for any type of malignancy, the American Urological Association, American Society of Clinical Oncology, American Society for Radiation Oncology and Society of Urologic Oncology have formulated an evidence-based guideline based on a risk-stratified clinical framework for the management of muscle-invasive urothelial bladder cancer. This document is designed to be used in conjunction with the associated treatment algorithm. CONCLUSIONS: The intensity and scope of care for muscle-invasive bladder cancer should focus on the patient, disease and treatment response characteristics. This guideline attempts to improve a clinician's ability to evaluate and treat each patient, but higher quality evidence in future trials will be essential to improve level of care for these patients.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Chang SS, Bochner BH, Chou R, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol. 2017. PMID: 28456635. doi:10.1016/j.juro.2017.04.086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。